Phototherapy intelligent regulation and control device and control method thereof, electronic equipment and storage medium

Abstract

The embodiment of the invention provides a phototherapy intelligent regulation and control device, a control method thereof, electronic equipment and a storage medium, and belongs to the technical field of medical instruments. The phototherapy intelligent regulation and control device comprises a photon cap, a phototherapy module, a monitoring module and a processing module, the phototherapy module and the monitoring module are fixed on a clamping seat of the photon cap, and the processing module is connected with the phototherapy module and the monitoring module; wherein the phototherapy module is used for emitting first near-infrared light, and non-invasive therapy can be achieved in a non-invasive mode; the monitoring module is used for detecting the blood oxygen level of the cerebral cortex and sending the detected oxyhemoglobin concentration to the processing module for analysis, and can monitor and feed back data in real time, so that the treatment process is transparent; the processing module is used for regulating and controlling the treatment parameters of the first near-infrared light emitted by the phototherapy module according to the change speed of the oxyhemoglobin concentration, the treatment parameters can be automatically regulated and controlled according to the detected data, and the intelligent degree of treatment is improved.

Description

Technical Field

[0001] The present application relates to the field of medical device technology, and in particular to a light therapy intelligent control device and a control method thereof, an electronic device and a storage medium. Background Art

[0002] Alzheimer's disease (AD) is a degenerative disease of the central nervous system that mainly occurs in the elderly or pre-elderly and is the most common form of dementia. Its symptoms include memory impairment, aphasia, apraxia, agnosia, and visual-spatial ability impairment, often accompanied by changes in personality and behavior.

[0003] Currently, the diagnosis and treatment of Alzheimer's disease face many challenges, such as difficulty in early diagnosis, invasiveness of existing detection methods, and poor repeatability. In recent years, more and more studies have shown that photobiomodulation and Hertz photoacoustics have significant therapeutic effects on meningeal lymphatic vessels, and the use of near-infrared light transcranial irradiation can promote brain waste metabolism, thereby achieving the effect of treating Alzheimer's disease.

[0004] However, due to the different severity of symptoms and individual differences among Alzheimer's patients, different treatment parameters are required. However, the light therapy equipment for Alzheimer's treatment on the market generally requires therapists to manually adjust the treatment parameters, which is inconvenient to operate and has a low level of intelligence. In addition, due to the lack of real-time monitoring and feedback, it is difficult for therapists to understand the treatment effect and the patient's status during the treatment process. Summary of the invention

[0005] The main purpose of the embodiments of the present application is to propose a light therapy intelligent control device and its control method, electronic equipment and storage medium, aiming to achieve non-invasive treatment and real-time monitoring, and improve the intelligence level of treatment.

[0006] To achieve the above-mentioned purpose, one aspect of an embodiment of the present application provides a light therapy intelligent control device, comprising a photon cap, a light therapy module, a monitoring module and a processing module, wherein the light therapy module and the monitoring module are fixed on a holder of the photon cap, and the processing module is connected to the light therapy module and the monitoring module respectively;

[0007] Wherein, the phototherapy module is used to emit a first near-infrared light, and the wavelength range of the first near-infrared light is 700nm to 1000nm;

[0008] The monitoring module is used to detect the blood oxygen level in the cerebral cortex and send the detected oxygenated hemoglobin concentration to the processing module for analysis;

[0009] The processing module is used to adjust the treatment parameters of the first near-infrared light emitted by the phototherapy module according to the change rate of the oxygenated hemoglobin concentration.

[0010] In some embodiments, the phototherapy modules and the monitoring modules are evenly and alternately distributed in a first area of ​​the photonic cap, wherein the first area is arranged corresponding to the position of the back of the patient's head.

[0011] In some embodiments, the phototherapy module includes a plurality of phototherapy devices, which are arranged corresponding to the meningeal lymphatic vessel area to form a treatment channel.

[0012] In some embodiments, each of the phototherapy devices is equipped with a first temperature sensor, which is used to detect the operating temperature of the treatment channel.

[0013] In some embodiments, the monitoring module includes a transmitting probe and a receiving probe;

[0014] The transmitting probe is used to emit a second near-infrared light, the wavelength of the second near-infrared light is in the range of 700nm to 1000nm, and the wavelength of the second near-infrared light is not equal to the wavelength of the first near-infrared light;

[0015] The receiving probe is used to receive the second near-infrared light.

[0016] In some embodiments, the processing module is further used to filter out the first near-infrared light generated by the light therapy module.

[0017] In some embodiments, the treatment parameters of the first near-infrared light include light intensity and treatment frequency.

[0018] To achieve the above purpose, another aspect of the embodiment of the present application provides a control method of a light therapy intelligent control device, which is applied to the aforementioned system light therapy intelligent control device. The control method includes the following steps:

[0019] Emitting a first near-infrared light through a phototherapy module, wherein the wavelength of the first near-infrared light is in a range of 700 nm to 1000 nm;

[0020] The monitoring module detects the blood oxygen level in the cerebral cortex and sends the detected oxygenated hemoglobin concentration to the processing module for analysis;

[0021] The processing module is used to adjust the treatment parameters of the first near-infrared light emitted by the phototherapy module according to the change rate of the oxygenated hemoglobin concentration.

[0022] To achieve the above-mentioned purpose, another aspect of an embodiment of the present application provides an electronic device, the electronic device comprising a memory and a processor, the memory storing a computer program, and the processor implementing the above-mentioned control method when executing the computer program.

[0023] To achieve the above-mentioned purpose, another aspect of an embodiment of the present application provides a computer-readable storage medium, wherein the computer-readable storage medium stores a computer program, and the computer program implements the above-mentioned control method when executed by a processor.

[0024] The embodiments of the present application include at least the following beneficial effects: The present application provides a phototherapy intelligent control device and a control method thereof, an electronic device and a storage medium, the phototherapy intelligent control device includes a photon cap, a phototherapy module, a monitoring module and a processing module, the phototherapy module and the monitoring module are fixed on the holder of the photon cap, and the processing module is respectively connected to the phototherapy module and the monitoring module; wherein the phototherapy module is used to emit a first near-infrared light, and can achieve non-invasive treatment in a non-invasive manner; the monitoring module is used to detect the blood oxygen level in the cerebral cortex, and send the detected oxygenated hemoglobin concentration to the processing module for analysis, and can monitor in real time and feedback data to make the treatment process transparent; the processing module is used to control the treatment parameters of the first near-infrared light emitted by the phototherapy module according to the changing speed of the oxygenated hemoglobin concentration, and can automatically control the treatment parameters according to the detected data, thereby improving the intelligence level of the treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 It is a structural framework diagram of the light therapy intelligent control device provided in the embodiment of the present application;

[0026] Figure 2 is a schematic diagram of the structure of a receiving probe provided in an embodiment of the present application;

[0027] Figure 3 It is a flowchart of a control method of a light therapy intelligent control device provided in an embodiment of the present application;

[0028] Figure 4 It is a schematic diagram of the hardware structure of the electronic device provided in the embodiment of the present application.

[0029] Reference numerals:

[0030] Photon cap 100 , flat cable 101 , plug 102 , socket 103 , Velcro 104 , strap 105 , phototherapy module 110 , monitoring module 120 , transmitting probe 121 , receiving probe 122 , filter 123 , processing module 130 , host 131 , LCD display 132 , switch 133 . DETAILED DESCRIPTION

[0031] In order to make the purpose, technical solutions and advantages of the present application clearer, the present application is further described in detail below in conjunction with the accompanying drawings and examples. It should be understood that the specific embodiments described herein are only used to explain the present application and are not intended to limit the present application. When the following description refers to the drawings, unless otherwise indicated, the same numbers in different drawings represent the same or similar elements. The embodiments described in the following exemplary embodiments do not represent all embodiments consistent with the embodiments of the present application. They are only examples of devices and methods consistent with some aspects of the embodiments of the present application as detailed in the attached claims.

[0032] It is understood that the terms "first", "second", etc. used in this application can be used to describe various concepts in this article, but unless otherwise specified, these concepts are not limited by these terms. These terms are only used to distinguish one concept from another concept. For example, without departing from the scope of the embodiment of the present application, the first information may also be referred to as the second information, and similarly, the second information may also be referred to as the first information. Depending on the context, the words "if" and "if" as used herein can be interpreted as "at the time of" or "when" or "in response to determination".

[0033] The terms "at least one", "multiple", "each", "any", etc. used in this application, at least one includes one, two or more, multiple includes two or more, each refers to each of the corresponding multiple, and any refers to any one of the multiple.

[0034] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein are only for the purpose of describing the embodiments of this application and are not intended to limit this application.

[0035] Before describing the embodiments of the present application in detail, some related technologies involved in the embodiments of the present application are first described.

[0036] Alzheimer's disease is the most common type of dementia, accounting for about 70% of all dementia cases. Most AD cases occur in the elderly and pre-elderly, and it is a common degenerative disease of the central nervous system. Its main pathological features are β-amyloid protein (amy l oidβ-protein, Aβ) plaque deposition and neurofibrillary tangles, as well as loss of neurons and synapses in specific brain regions and vascular amyloidosis. The main manifestations are progressive cognitive dysfunction and behavioral impairment. Clinical manifestations mainly include memory loss, cognitive impairment, executive dysfunction, and personality and behavioral changes. According to data released by the International Alzheimer's Disease Association (ADI), there are at least 50 million dementia patients in the world, and it is expected to reach 152 million by 2050, of which about 60%-70% are Alzheimer's patients. AD is not only a serious health problem, but also a difficult family and social problem. For families with Alzheimer's patients, they not only suffer mentally, but also face a very realistic burden of care and nursing. As the number of AD patients increases, the entire society will face a heavier economic burden.

[0037] Meningeal lymphatic vessels, also known as the "meningeal lymphatic system", are a network of macromolecules draining from the central nervous system sheath. They are connected to the peripheral immune system and are responsible for draining macromolecules from the cerebrospinal fluid and interstitial fluid of the central nervous system to the cervical lymph nodes, effectively removing "garbage" from the brain, such as protein plaques and cell fragments typical of Alzheimer's disease. Once this transport system is blocked, it will aggravate the decline of cognitive function and easily induce a series of brain diseases related to aging. In 2015, Nature magazine first revealed the existence of the meningeal lymphatic vascular system (mLVs). This discovery subsequently attracted widespread attention in the scientific research community, especially its increasingly prominent role in aging and neurodegenerative diseases. As a key pathway for the removal of metabolic waste and the regulation of immune responses in the central nervous system, mLVs are particularly important for the removal of β-amyloid protein (Aβ) in Alzheimer's disease (AD). The impairment or restoration of its function directly affects the progression of AD, making mLVs a potential target for the treatment of AD. Given the easily accessible location of mLVs in the dura mater, scientists have explored the possibility of noninvasively modulating their function, opening up new avenues for intervention in neuroimmune diseases.

[0038] Photobiomodulation (PBM), especially the use of red or near-infrared light, as a non-invasive treatment, has shown efficacy in a variety of medical fields, including promoting wound healing, reducing pain and inflammation. In neurodegenerative disease model studies, transcranial PBM has been shown to effectively regulate the activity of neurons and microglia, thereby slowing neuronal damage and delaying disease progression. Clinical trials have also further supported the positive role of PBM in improving symptoms in patients with AD and Parkinson's disease (PD). The latest Nature Communications study has made a breakthrough in showing that transcranial PBM with a wavelength of 808nm can significantly promote the recovery of lymphatic drainage function by activating mLVs endothelial cells in AD mice, thereby alleviating AD pathological changes and improving cognitive function. This discovery provides new hope and direction for the use of non-invasive PBM technology to regulate mLVs function to treat neurodegenerative diseases.

[0039] Related studies also used the MES method to analyze and compare the differences in the complexity of blood oxygen signals in the brains of AD patients and healthy control subjects, and found that the MSE value of AD patients was significantly lower than that of the healthy control group, and the entropy values ​​in multiple functional networks were significantly reduced, and the reduction in the entropy value of the ventral attention network showed a marginally significant positive correlation with the patient's overall cognitive performance. Therefore, during the treatment process, the blood oxygen level in the cerebral cortex of Alzheimer's patients can be used as a basis for judging the effectiveness of treatment. By adjusting the device parameters, the blood oxygen concentration in the patient's cerebral cortex can always be kept at a high level, thereby achieving the best treatment effect.

[0040] However, the existing technologies for the treatment of Alzheimer's disease have some shortcomings that affect the treatment effect: there is currently a lack of instruments on the market that can improve the function of the meningeal lymphatic vessels through phototherapy, thereby achieving a therapeutic effect on Alzheimer's disease; at the same time, there is a lack of real-time monitoring and feedback during the treatment process; and the meningeal lymphatic vascular phototherapy equipment currently on the market for the treatment of Alzheimer's disease generally requires therapists to manually adjust the treatment parameters, which is inconvenient to operate, has a low degree of intelligence, and lacks the storability of data during the treatment process.

[0041] In view of this, an intelligent light therapy control device is provided in the embodiment of the present application, referring to Figure 1 , including a photon cap 100, a phototherapy module 110, a monitoring module 120 and a processing module 130. The phototherapy module and the monitoring module are fixed on the holder of the photon cap, and the processing module is connected to the phototherapy module and the monitoring module respectively.

[0042] The phototherapy module is used to emit a first near-infrared light, and the wavelength range of the first near-infrared light is 700nm to 1000nm.

[0043] The monitoring module is used to detect the blood oxygen level in the cerebral cortex and send the detected oxygenated hemoglobin concentration to the processing module for analysis.

[0044] The processing module is used to adjust the treatment parameters of the first near-infrared light emitted by the phototherapy module according to the change rate of the oxygenated hemoglobin concentration.

[0045] Specifically, the phototherapy intelligent control device consists of a photon cap, a phototherapy module, a monitoring module and a processing module. The phototherapy module is fixed on the base of the photon cap, close to the scalp, and the processing module is connected to the phototherapy module and the monitoring module respectively. By combining multiple functions such as phototherapy and brain function detection, non-invasive treatment is achieved.

[0046] Preferably, since the absorption coefficients of oxygenated hemoglobin and deoxygenated hemoglobin are exactly equal when the wavelength of near-infrared light is around 808 nm, near-infrared light with a wavelength of 808 nm can be used as the first near-infrared light. The phototherapy module emits the first near-infrared light with sufficient energy to perform phototherapy on the patient's meningeal lymphatic vessels, and the monitoring module is used to detect the blood oxygen level in the cerebral cortex, and the detected oxygenated hemoglobin concentration is sent to the processing module for analysis. The processing module automatically adjusts the treatment parameters of the phototherapy module for emitting near-infrared light according to the oxygenated hemoglobin concentration, so that the blood oxygen content in the patient's cerebral cortex is always at a high level, thereby achieving the purpose of efficient treatment.

[0047] It can be understood that within the range of 700nm to 1000nm, near-infrared light causes relatively little damage to human tissue and is suitable as a non-invasive treatment method. At the same time, near-infrared light within this wavelength range can penetrate the scalp to reach the area where the meningeal lymphatic vessels are located. The use of near-infrared light with a wavelength of 808nm as the first near-infrared light is only exemplary. The first near-infrared light emitted by the phototherapy module can select near-infrared light between 700nm and 1000nm according to individual patient differences and treatment conditions, and the embodiments of the present application do not impose specific limitations.

[0048] In some embodiments, the light therapy intelligent control device also includes a cable 101 , a plug 102 , and a socket 103 .

[0049] Specifically, refer to Figure 1 One end of the phototherapy module and the monitoring module are connected to the first socket through wires, and a second socket is provided on the processing module. The phototherapy intelligent control device connects the processing module to the phototherapy module and the monitoring module respectively through a flat cable, wherein a first plug is provided at the first end of the flat cable, and a second plug is provided at the second end of the flat cable, the first plug is connected to the first socket, and the second plug is connected to the second socket.

[0050] In some embodiments, the phototherapy modules and the monitoring modules are evenly and alternately distributed in a first area of ​​the photonic cap, wherein the first area is arranged corresponding to the position of the back of the patient's head.

[0051] It is understandable that the best phototherapy position is the back of the patient's head. Figure 1 , the probes of the five monitoring modules and the phototherapy modules are alternately distributed in the rear half of the photon cap (i.e., the first area), where the first area corresponds to the back of the patient's head. By alternating the phototherapy modules and the monitoring modules, it is possible to ensure that each phototherapy area has a corresponding probe for real-time detection, thereby providing more comprehensive treatment monitoring data and helping to more accurately evaluate the treatment effect.

[0052] In some embodiments, the phototherapy module includes multiple phototherapy devices, which are arranged corresponding to the meningeal lymphatic vessel area to form a treatment channel.

[0053] For example, reference Figure 1 , Figure 1 The phototherapy module is composed of 4 phototherapy devices that can emit the first near-infrared light. The phototherapy devices are set corresponding to the meningeal lymphatic vessel area to form a treatment channel. The near-infrared light emitted by the phototherapy device is used as a non-invasive treatment method. Optionally, transcranial PBM with a wavelength of 700nm is used to activate the activity of endothelial cells in the meningeal lymphatic system, effectively promoting the recovery of lymphatic drainage function, thereby alleviating AD pathological changes and improving patients' cognitive function, and treating neurodegenerative diseases.

[0054] In this embodiment, the position of the phototherapy device is designed according to the distribution characteristics of the meningeal lymphatic vessels, so that the phototherapy intelligent control device can more accurately irradiate light to the area where the meningeal lymphatic vessels are located, thereby more effectively promoting the function of the lymphatic vessels, accelerating the discharge of waste and harmful substances, and improving the brain's microenvironment.

[0055] Furthermore, in some embodiments, each phototherapy device is equipped with a first temperature sensor, and the first temperature sensor is used to detect the working temperature of the treatment channel.

[0056] Specifically, considering that the phototherapy device generates heat during operation, if the operating temperature is too high, it may cause discomfort or damage to the patient's scalp. Therefore, each phototherapy device is built with a first temperature sensor to monitor the operating temperature of the treatment channel in real time.

[0057] Exemplarily, the preset channel temperature upper limit is 39 degrees. When the first sensor detects that the operating temperature exceeds 39 degrees, the processing module controls the phototherapy device to stop running to prevent the phototherapy device from having too high power during the treatment process, causing severe fever and making the patient feel uncomfortable.

[0058] In some embodiments, the monitoring module includes a transmitting probe 121 and a receiving probe 122; wherein the transmitting probe is used to transmit a second near-infrared light, the wavelength range of the second near-infrared light is 700nm to 1000nm, and the wavelength of the second near-infrared light is not equal to the wavelength of the first near-infrared light; the receiving probe is used to receive the second near-infrared light.

[0059] Specifically, refer to Figure 1 , among the probes of the 5 monitoring modules, each probe group consists of 1 transmitting probe and 2 receiving probes, and the two receiving probes are respectively distributed on the left and right sides of the transmitting probe, forming a total of 10 detection channels. Among them, the transmitting probe is used to emit the second near-infrared light, the wavelength range of the second near-infrared light is 700nm to 1000nm, and the wavelength of the second near-infrared light is not equal to the wavelength of the first near-infrared light. Preferably, the transmitting probe can emit the second near-infrared light with a wavelength of 760nm. The receiving probe only receives the second near-infrared light generated by the transmitting probe, so that the detection result is more accurate.

[0060] In some embodiments, the transmitting probe is also used to emit a third near-infrared light, wherein the wavelength of the third near-infrared light ranges from 830nm to 910nm, and the wavelength of the third near-infrared light is not equal to the wavelength of the first near-infrared light and the second near-infrared light; the receiving probe is also used to receive the third near-infrared light.

[0061] For example, 808nm near-infrared light is generally used as a reference wavelength in monitoring. Since the absorption coefficients of oxyhemoglobin and deoxyhemoglobin are equal at this time, in order to further distinguish the concentration of oxyhemoglobin and the concentration of deoxyhemoglobin, the transmitting probe can also emit a third near-infrared light with a wavelength that is not equal to the first near-infrared light and the second near-infrared light for detection, and the receiving probe can receive the third near-infrared light to identify the concentration of oxyhemoglobin and the concentration of deoxyhemoglobin to improve the accuracy of detection.

[0062] Furthermore, since the monitoring module measures the blood oxygen level in the cerebral cortex by emitting near-infrared light of a specific wavelength and detecting its reflected or transmitted light, and considering that in addition to the second near-infrared light generated by the transmitting probe, there is also the first near-infrared light generated by the phototherapy module during the treatment process, if all near-infrared light is received, the first near-infrared light generated by the phototherapy module will interfere with the measurement results. Therefore, in order to achieve parallel operation of these two functions without interfering with each other, in some embodiments, the processing module is also used to filter out the first near-infrared light generated by the phototherapy module.

[0063] Specifically, considering that the wavelength of the near-infrared light generated by the phototherapy module and the transmitting probe can be set within 700nm to 1000nm according to actual conditions, in order to adapt to the wavelength change, the first near-infrared light generated by the phototherapy module is optionally filtered out by the processing module. For example, the first near-infrared light of 900nm is modulated to a 10kHz carrier in advance, and the second near-infrared light of 800nm ​​is modulated to a 15kHz carrier. Then, after the receiving probe receives the signal, the processing module uses Fourier transform to demodulate the intensity of different frequencies, and adjusts the filter parameters according to the wavelength of the first near-infrared light and the wavelength of the second near-infrared light, thereby filtering out the first near-infrared light generated by the phototherapy module and reducing interference with the measurement results.

[0064] It should be noted that in signals and systems, high-frequency signals are usually considered to be pseudo-DC signals. On the basis of high-frequency signals, the amplitude of high-frequency signals is modulated at a low frequency to control the therapeutic frequency of near-infrared light.

[0065] It can be understood that the type of carrier wave can be a sine wave, a triangle wave, a square wave, etc., and the frequency of the carrier wave can be other high-frequency frequencies besides 10kHz and 15kHz. The embodiments of the present application are not specifically limited as long as the modulation of near-infrared light can be achieved.

[0066] In another embodiment, referring to Figure 2 A filter 123 is built into the receiving probe, and the filter is used to filter out the first near-infrared light generated by the phototherapy module.

[0067] Specifically, when the wavelength of the first near-infrared light emitted by the phototherapy module is fixed, a filter can be built into the receiving probe to filter out the near-infrared light of a preset wavelength. For example, when the wavelength of the first near-infrared light is 808nm and the wavelength of the second near-infrared light is 760nm, the near-infrared light of 808nm can be filtered out by the filter to filter out the first near-infrared light generated by the phototherapy module, so that the receiving probe only receives the second near-infrared light generated by the transmitting probe.

[0068] In this embodiment, by filtering out unnecessary wavelengths of light, the accuracy of the monitoring module in detecting parameters such as blood oxygen concentration can be improved, which helps to accurately evaluate the treatment effect, monitor changes in the disease, and adjust the treatment plan in a timely manner.

[0069] In some embodiments, the treatment parameters of the first near-infrared light include light intensity and treatment frequency.

[0070] It should be noted that the adjustable treatment parameters of the first near-infrared light include light intensity and treatment frequency. For example, the power of the phototherapy device is controlled by adjusting the current of the treatment channel, so as to achieve the purpose of adjustable light intensity of the first near-infrared light; or, according to the needs of the patient and the treatment plan, the flashing frequency of the lamp beads in the phototherapy device is adjusted to change the treatment frequency of the first near-infrared light.

[0071] The following is a detailed introduction and description of the solution of the embodiment of the present invention in conjunction with a specific application example.

[0072] Reference Figure 1 The phototherapy intelligent control device is composed of a phototherapy module, a monitoring module, a processing module and supporting software.

[0073] The phototherapy module consists of 4 phototherapy devices that can emit 808nm near-infrared light and have built-in temperature sensors, forming 4 treatment channels. The light intensity is adjustable, and the flashing frequency of the lamp beads can be adjusted to 10Hz, 20Hz, 30Hz, and 40Hz. The phototherapy device is fixed on the card holder on the photon cap, close to the scalp.

[0074] The monitoring module is used to measure the concentration of oxygenated hemoglobin and deoxygenated hemoglobin in the brain, detect the temperature information of the four phototherapy devices, the temperature inside the body, and the ambient temperature. It consists of 5 sets of probes and 6 temperature sensors, each set of probes consists of 1 transmitting probe and 2 receiving probes. The 5 sets of probes are alternately distributed with the phototherapy devices, so that the information of the blood oxygen level of the cerebral cortex in the phototherapy area can be accurately detected.

[0075] The processing module is composed of a host 131, a liquid crystal display 132, a second temperature sensor, a Bluetooth module, a lithium battery, and a buzzer. The LCD display can display information such as power, ambient temperature, temperature inside the fuselage, working temperature of four treatment channels, and Bluetooth connection status. The host uses a GD32 single-chip microcomputer as a control unit, and a switch 133 is also provided on the surface of the host. In order to prevent accidental touching of the switch, a push-type switch is not used, but a left and right push-pull switch is used. The Bluetooth module can connect the processing module to the supporting software installed in the computer to achieve the purpose of observable information and adjustable parameters. When the power is lower than the preset power or the temperature inside the fuselage is higher than the preset fuselage temperature, the buzzer will sound. After the supporting software is connected to the processing module by Bluetooth, the patient's cerebral cortex blood oxygen level information detected by the monitoring module, as well as the opening and closing of the four channels of the phototherapy module and the light intensity and flickering frequency of the first near-infrared light of 808nm can be viewed through the software.

[0076] It should be noted that in addition to automatically adjusting the treatment parameters of the first near-infrared light according to the blood oxygen level information, the light intensity and treatment frequency of the 808nm near-infrared light of the phototherapy module can also be manually adjusted in the software, or the switch of the detection channel in the monitoring module can be set in the software, and the probe of the monitoring module can be selected according to the number of phototherapy devices turned on and the position of the turned-on phototherapy devices.

[0077] Furthermore, in order to facilitate fixing the host on the patient's arm, straps 105 with Velcro 104 are designed on the left and right sides of the processing module.

[0078] In addition, Velcro A and Velcro B are provided on the left and right sides of the photon cap respectively. Before use, Velcro A and Velcro B can be fitted together to prevent the phototherapy module and the monitoring module from falling off the holder of the photon cap.

[0079] Before the treatment begins, first connect the phototherapy device, the transmitting probe and the receiving probe to the host with a flat cable. After the patient wears the photon cap, insert the phototherapy device, the transmitting probe and the receiving probe, and stick Velcro A and Velcro B together, and then fix the host to the patient's arm with a strap. To avoid interference from ambient light, the patient can also wear a light-shielding cap to make the monitored cerebral cortex blood oxygen information more accurate.

[0080] Next, turn on the host switch and supporting software, connect via Bluetooth through the software, set the treatment channel and detection channel in the software, and select the data storage location.

[0081] Then, check whether the phototherapy intelligent control device is worn properly and connected correctly. If it is worn properly and connected correctly, treatment can be carried out.

[0082] During the treatment process, it is assumed that the device power supply of the phototherapy intelligent control device is a 6V DC power supply. First, determine the working frequency of the phototherapy device, the time is 4 minutes, the phototherapy device uses 200mA current, that is, the working power is 1.2W, and the patient is treated at a frequency of 10Hz in the first minute, 20Hz in the second minute, 30Hz in the third minute, and 40Hz in the fourth minute. After the monitoring module calculates the average concentration change rate of oxygenated hemoglobin per minute, the operating frequency with the fastest increase in the patient's oxygenated hemoglobin concentration is selected as the patient's treatment frequency.

[0083] After a period of treatment at the selected treatment frequency, the concentration of oxygenated hemoglobin will remain unchanged. Then, the power of the phototherapy device will be adjusted according to the concentration of oxygenated hemoglobin in the patient's brain. The initial current will be slowly increased from 200mA. If the concentration of oxygenated hemoglobin also increases, the control current will continue to increase until the concentration of oxygenated hemoglobin shows a slight downward trend.

[0084] It should be noted that the upper limit of the current is 400mA. If the concentration of oxygenated hemoglobin always shows an increasing trend and does not show a downward trend, after reaching the upper limit of the current, stop increasing the current and use 400mA as the working current of the phototherapy device.

[0085] If the oxygenated hemoglobin concentration immediately shows a downward trend as soon as the initial current starts to increase from 200mA, the phototherapy device will stop increasing the initial current from 200mA and change to decreasing it. At this time, the oxygenated hemoglobin concentration in the patient's brain begins to rise, and the current decreases until the oxygenated hemoglobin concentration shows a downward trend.

[0086] During the entire treatment process, due to individual differences among patients and varying degrees of symptom severity, the parameters of the therapeutic device can be fine-tuned according to the oxygenated hemoglobin concentration so that the patient's cerebral cortex blood oxygen level is always at a high level, thereby achieving the best treatment effect.

[0087] The embodiment of the present application is aimed at the lack of instruments on the market that can improve the function of meningeal lymphatic vessels through phototherapy, thereby achieving therapeutic effects on Alzheimer's disease. Through the integration of optical detection and regulation, and the use of brain function imaging, the changes in the patient's cerebral cortex blood oxygen concentration can be monitored in real time. These data are fed back to the therapist, patient and family members in the form of a curve graph on the computer screen, making it easier for the therapist to understand the treatment effect and the patient's morphology during the treatment process, making the treatment process transparent, and alleviating the anxiety of the patient and his family members.

[0088] In addition, the meningeal lymphatic vascular phototherapy devices currently on the market for the treatment of Alzheimer's disease generally require therapists to manually adjust the treatment parameters, which is inconvenient to operate and has a low level of intelligence. The phototherapy intelligent control device provided by this application can store the blood oxygen level information of the cerebral cortex detected during the treatment process in the computer hard disk. Through the subsequent analysis of these data, it helps therapists to more accurately judge the treatment effect of patients and adjust the subsequent treatment plan.

[0089] Figure 3 It is an optional flow chart of a control method for a light therapy intelligent control device provided in an embodiment of the present application, which is applied to a light therapy intelligent control device. The control method may include but is not limited to steps S301 to S303.

[0090] Step S301, emitting a first near-infrared light through a phototherapy module, wherein a wavelength range of the first near-infrared light is 700 nm to 1000 nm.

[0091] Step S302, detecting the blood oxygen level of the cerebral cortex through the monitoring module, and sending the detected oxygenated hemoglobin concentration to the processing module for analysis.

[0092] Step S303: The processing module regulates the treatment parameters of the first near-infrared light emitted by the phototherapy module according to the change rate of the oxygenated hemoglobin concentration.

[0093] Specifically, the phototherapy module is first controlled to emit a first near-infrared light with a wavelength between 700nm and 1000nm to perform phototherapy on the meningeal lymphatic vessels. At the same time, the patient's cerebral cortex blood oxygen level is detected by the monitoring module, and the detected oxygenated hemoglobin concentration is sent to the processing module for analysis. After receiving the data sent by the monitoring module, the processing module adjusts the treatment parameters of the first near-infrared light emitted by the phototherapy module according to the change rate of the oxygenated hemoglobin concentration, and finds the intensity and treatment frequency of the near-infrared light with the best treatment effect according to the severity of the patient's symptoms and individual differences, so that the patient's cerebral cortex blood oxygen level is always at a high level.

[0094] In this embodiment, non-invasive treatment can be achieved by performing phototherapy and monitoring the blood oxygen concentration of the cerebral cortex in a non-invasive manner, without the need for surgery or injections on the patient, and with high safety and comfort. At the same time, the monitoring module is used to record and display the blood oxygen concentration of the cerebral cortex in real time, thereby providing instant feedback on the functional state of the brain, which is helpful for evaluating the treatment effect, monitoring changes in the disease, and timely adjusting the treatment plan.

[0095] In addition, the processing module can automatically adjust the parameters of the first near-infrared light generated by the phototherapy module according to the patient's cerebral cortex blood oxygen level information during treatment, so that the blood oxygen concentration in the patient's cerebral cortex is always at a high level. This automated treatment can save a lot of manpower and material resources and improve the treatment effect.

[0096] The embodiment of the present application also provides an electronic device, the electronic device includes a memory and a processor, the memory stores a computer program, and the processor implements the control method of the above-mentioned light therapy intelligent control device when executing the computer program. The electronic device can be any intelligent terminal including a tablet computer, a mobile phone, etc.

[0097] It can be understood that the contents of the above method embodiments are all applicable to the present device embodiments, the functions specifically implemented by the present device embodiments are the same as those of the above method embodiments, and the beneficial effects achieved are also the same as those achieved by the above method embodiments.

[0098] See also Figure 4 , Figure 4 The hardware structure of an electronic device of another embodiment is illustrated, and the electronic device includes:

[0099] The processor 401 may be implemented by a general-purpose CPU (Central Processing Unit), a microprocessor, an application-specific integrated circuit (ASIC), or one or more integrated circuits, and is used to execute relevant programs to implement the technical solutions provided in the embodiments of the present application.

[0100] The memory 402 can be implemented in the form of a read-only memory (ROM), a static storage device, a dynamic storage device, or a random access memory (RAM). The memory 402 can store an operating system and other application programs. When the technical solution provided in the embodiment of this specification is implemented by software or firmware, the relevant program code is stored in the memory 402, and the processor 401 calls and executes the control method of the light therapy intelligent control device of the embodiment of this application;

[0101] Input / output interface 403, used to implement information input and output;

[0102] Communication interface 404, used to realize communication interaction between the device and other devices, which can be realized through wired mode (such as USB, network cable, etc.) or wireless mode (such as mobile network, WI FI, Bluetooth, etc.);

[0103] Bus 405 , which transmits information between various components of the device (e.g., processor 401 , memory 402 , input / output interface 403 , and communication interface 404 );

[0104] The processor 401 , the memory 402 , the input / output interface 403 and the communication interface 404 are connected to each other in communication within the device via the bus 405 .

[0105] An embodiment of the present application also provides a computer-readable storage medium, which stores a computer program. When the computer program is executed by a processor, the control method of the above-mentioned light therapy intelligent control device is implemented.

[0106] It can be understood that the contents of the above method embodiments are all applicable to the present storage medium embodiments, the functions specifically implemented by the present storage medium embodiments are the same as those of the above method embodiments, and the beneficial effects achieved are also the same as those achieved by the above method embodiments.

[0107] The memory, as a non-transient computer-readable storage medium, can be used to store non-transient software programs and non-transient computer executable programs. In addition, the memory may include a high-speed random access memory, and may also include a non-transient memory, such as at least one disk storage device, a flash memory device, or other non-transient solid-state storage device. In some embodiments, the memory may optionally include a memory remotely disposed relative to the processor, and these remote memories may be connected to the processor via a network. Examples of the above-mentioned network include, but are not limited to, the Internet, an intranet, a local area network, a mobile communication network, and combinations thereof.

[0108] The embodiments described in the embodiments of the present application are intended to more clearly illustrate the technical solutions of the embodiments of the present application and do not constitute a limitation on the technical solutions provided in the embodiments of the present application. Those skilled in the art will appreciate that with the evolution of technology and the emergence of new application scenarios, the technical solutions provided in the embodiments of the present application are also applicable to similar technical problems.

[0109] Those skilled in the art will appreciate that the technical solutions shown in the figures do not constitute a limitation on the embodiments of the present application, and may include more or fewer steps than shown in the figures, or a combination of certain steps, or different steps.

[0110] The system embodiments described above are merely illustrative, and the units described as separate components may or may not be physically separated, that is, they may be located in one place or distributed on multiple network units. Some or all of the modules may be selected according to actual needs to achieve the purpose of the present embodiment.

[0111] Those skilled in the art will appreciate that all or some of the steps in the methods disclosed above, and the functional modules / units in the systems and devices may be implemented as software, firmware, hardware, or a suitable combination thereof.

[0112] The terms "first", "second", "third", "fourth", etc. (if any) in the specification of the present application and the above-mentioned drawings are used to distinguish similar objects, and are not necessarily used to describe a specific order or sequence. It should be understood that the data used in this way can be interchangeable where appropriate, so that the embodiments of the present application described herein can be implemented in an order other than those illustrated or described herein. In addition, the terms "including" and "having" and any of their variations are intended to cover non-exclusive inclusions, for example, a process, method, system, product or device comprising a series of steps or units is not necessarily limited to those steps or units clearly listed, but may include other steps or units that are not clearly listed or inherent to these processes, methods, products or devices.

[0113] The preferred embodiments of the present invention are described above with reference to the accompanying drawings, but the scope of the rights of the present invention is not limited thereto. Any modification, equivalent substitution and improvement made by a person skilled in the art without departing from the scope and essence of the present invention should be within the scope of the rights of the present invention.

Claims

1. A light therapy intelligent control device, characterized in that: It includes a photon cap, a phototherapy module, a monitoring module and a processing module, wherein the phototherapy module and the monitoring module are fixed on a holder of the photon cap, and the processing module is connected to the phototherapy module and the monitoring module respectively; Wherein, the phototherapy module is used to emit a first near-infrared light, and the wavelength range of the first near-infrared light is 700nm to 1000nm; The monitoring module is used to detect the blood oxygen level in the cerebral cortex and send the detected oxygenated hemoglobin concentration to the processing module for analysis; The processing module is used to adjust the treatment parameters of the first near-infrared light emitted by the phototherapy module according to the change rate of the oxygenated hemoglobin concentration.

2. The light therapy intelligent control device according to claim 1, characterized in that: The phototherapy modules and the monitoring modules are evenly and alternately distributed in a first area of ​​the photon cap, wherein the first area is arranged corresponding to the position of the back of the patient's head.

3. The light therapy intelligent control device according to claim 1, characterized in that: The phototherapy module includes a plurality of phototherapy devices, which are arranged corresponding to the meningeal lymphatic vessel area to form a treatment channel.

4. The light therapy intelligent control device according to claim 3, characterized in that: Each of the phototherapy devices is equipped with a first temperature sensor, which is used to detect the working temperature of the treatment channel.

5. The light therapy intelligent control device according to claim 1, characterized in that: The monitoring module includes a transmitting probe and a receiving probe; The transmitting probe is used to emit a second near-infrared light, the wavelength of the second near-infrared light is in the range of 700nm to 1000nm, and the wavelength of the second near-infrared light is not equal to the wavelength of the first near-infrared light; The receiving probe is used to receive the second near-infrared light.

6. The light therapy intelligent control device according to claim 5, characterized in that: The processing module is also used to filter out the first near-infrared light generated by the phototherapy module.

7. The light therapy intelligent control device according to claim 1, characterized in that: The treatment parameters of the first near-infrared light include light intensity and treatment frequency.

8. A control method for a light therapy intelligent control device, characterized in that: Applied to the light therapy intelligent control device as claimed in claim 1, the control method comprises the following steps: Emitting a first near-infrared light through a phototherapy module, wherein the wavelength of the first near-infrared light is in a range of 700 nm to 1000 nm; The monitoring module detects the blood oxygen level in the cerebral cortex and sends the detected oxygenated hemoglobin concentration to the processing module for analysis; The processing module is used to adjust the treatment parameters of the first near-infrared light emitted by the phototherapy module according to the change rate of the oxygenated hemoglobin concentration.

9. An electronic device, characterized in that: The electronic device comprises a memory and a processor, the memory stores a computer program, and the processor implements the control method of claim 8 when executing the computer program.

10. A computer-readable storage medium storing a computer program, characterized in that: When the computer program is executed by a processor, the control method of claim 8 is implemented.

Images